Next Article in Journal
Excavating Precursors from Herb Pairs Polygala tenuifolia and Acori tatarinowii: Synthesis and Anticonvulsant Activity Evaluation of 3,4,5-Trimethoxycinnamic Acid (TMCA) Piperazine Amide Derivatives
Previous Article in Journal
Analysis of Upper Gastrointestinal Adverse Events Associated with Oral Anticoagulants and Potential Drug Interactions with Cardiovascular Drugs: Exploratory Study Using FDA Adverse Event Reporting System
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Advances in Fungal Natural Products: Insights into Bioactivity and Therapeutic Potential

Department of Medicinal Plant and Mushroom Biotechnology, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna, 30-688 Kraków, Poland
Pharmaceuticals 2025, 18(9), 1313; https://doi.org/10.3390/ph18091313
Submission received: 22 August 2025 / Accepted: 29 August 2025 / Published: 1 September 2025
Medicinal fungi represent a unique and underexploited reservoir of structurally diverse natural products with profound biological activities. These organisms produce a variety of secondary metabolites, including polysaccharides, terpenoids, phenolic compounds, alkaloids, proteins, and steroidal derivatives, which exhibit immunomodulatory, anti-inflammatory, antioxidant, antimicrobial, anticancer, and neuroprotective effects [1,2,3].
Advances in chemical biology, metabolomics, and pharmacology over the past decades have enabled more precise characterization of these compounds, facilitating their standardization, quality control, and potential integration into modern therapeutic strategies, such as adjuvant therapies, nutraceuticals, and functional foods [4,5,6]. Recent research has focused on understanding the molecular mechanisms underlying their bioactivity, particularly interactions with the immune system, cellular signaling pathways, and microbiota composition [7,8]. Biotechnological approaches, including fermentation and biotransformation, are increasingly employed to optimize the production of specific metabolites, while studies on synergistic effects with conventional drugs expand their potential applications in disease management [9].
Despite the longstanding interest in fungal metabolites, critical knowledge gaps remain regarding their precise mechanisms of action, optimal sources, and strategies for effective utilization in medicine. This Special Issue addresses these gaps by presenting recent advances in the isolation, characterization, and functional evaluation of bioactive fungal compounds [10,11,12,13,14,15].
The contributions to this issue provide a comprehensive overview of recent developments in the field. Coelho et al. investigated the therapeutic potential of exopolysaccharides from Auricularia auricula in mitigating DSS-induced colitis, demonstrating Dectin-1-mediated immunomodulation and microbiota remodeling [10]. Their findings underscore the intricate interplay between fungal polysaccharides, host immune responses, and gut microbiota, highlighting novel avenues for managing inflammatory bowel diseases [10,16,17].
Fu et al. explored the anti-inflammatory and immunomodulatory properties of Inonotus obliquus polysaccharides in rheumatoid arthritis using a combination of network pharmacology and experimental validation [12]. The study illustrates how integrating computational predictions with laboratory experiments can illuminate the mechanisms underlying fungal metabolite activity and guide the development of targeted therapeutics for autoimmune diseases [12,18].
Wang et al. expanded the chemical space of fungal metabolites by isolating ten novel sesquiterpenes and a new abietane-type diterpenoid from the marine fungus Eutypella sp., revealing potent immunosuppressive activity [15]. This work emphasizes the potential of marine-derived fungi as a reservoir of structurally unique and biologically active compounds that could serve as leads for drug development [15].
In the context of cancer therapy, Dourado et al. identified novel progesterone receptor inhibitors from fungal biotransformation metabolites, showcasing the application of bioinformatics tools in uncovering molecules with selective cytotoxicity against tumor cells [11]. Such approaches exemplify the integration of computational and experimental techniques in accelerating the discovery of bioactive fungal metabolites [11,12].
The interplay between environmental factors and secondary metabolite production is another theme highlighted in this issue. Santos et al. demonstrated that Mn(II) and Co(II) ions influence the anti-Candida metabolite profile of the endophytic fungus Aspergillus sp., revealing the importance of cultivation conditions in modulating fungal bioactivity [14].
On the other hand, Kała et al. illustrated the practical application of edible mushrooms, showing that coffee enriched with Cordyceps militaris and Hericium erinaceus fruiting bodies can serve as a convenient source of essential bioactive substances, merging dietary habits with health-promoting benefits. This work holds significant relevance for consumers, as it highlights the importance of selecting appropriate forms of supplementation to maximize health benefits [13].
Taken together, these articles highlight the vast therapeutic potential of fungal natural products while also demonstrating the diverse methodological approaches used to investigate them—from traditional biochemical assays to network pharmacology and metabolomics [10,11,12,13,14,15]. The studies collectively advance our understanding of fungal bioactive compounds, offering both mechanistic insights and translational opportunities for pharmaceutical development. Moreover, research on fungi has never progressed at such an accelerated pace, reflecting unprecedented advances in the identification, characterization, and application of bioactive fungal compounds [19,20].
Looking forward, several key areas for future research emerge. First, there is a need for standardized extraction and characterization methods to allow reproducible evaluation of bioactivity across studies. Second, integrating multi-omics approaches with in vivo validation will be critical to dissect the complex interactions between fungal metabolites, host systems, and microbiota. Third, exploring underinvestigated fungal species, including marine and endophytic fungi, may uncover novel chemical scaffolds with unique pharmacological profiles. Finally, clinical translation remains a major frontier, requiring rigorous evaluation of safety, bioavailability, and therapeutic efficacy.
In conclusion, this Special Issue underscores the promise of fungal natural products as a rich source of bioactive compounds with wide-ranging therapeutic applications. By bridging fundamental research and applied sciences, these studies provide a roadmap for future investigations that could transform fungal metabolites into clinically relevant interventions, addressing unmet medical needs while advancing our understanding of natural product biology.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; Supuran, C.T. Natural products in drug discovery: Advances and opportunities. Nat. Rev. Drug Discov. 2021, 20, 200–216. [Google Scholar] [CrossRef] [PubMed]
  2. Bell, V.; Silva, C.R.P.G.; Guina, J.; Fernandes, T.H. Mushrooms as future generation healthy foods. Front. Nutr. 2022, 9, 1050099. [Google Scholar] [CrossRef] [PubMed]
  3. Wadhwa, K.; Kapoor, N.; Kaur, H.; Abu-Seer, E.A.; Tariq, M.; Siddiqui, S.; Yadav, V.K.; Niazi, P.; Kumar, P.; Alghamdi, S. A Comprehensive review of the diversity of fungal secondary metabolites and their emerging applications in healthcare and environment. Mycobiology 2024, 52, 335–387. [Google Scholar] [CrossRef] [PubMed]
  4. Ayon, N.J.; Earp, C.E.; Gupta, R.; Butun, F.A.; Clements, A.E.; Lee, A.G.; Dainko, D.; Robey, M.T.; Khin, M.; Mardiana, L.; et al. Bioactivity-driven fungal metabologenomics identifies antiproliferative stemphone analogs and their biosynthetic gene cluster. Metabolomics 2024, 20, 90. [Google Scholar] [CrossRef] [PubMed]
  5. Mayirnao, H.; Sharma, K.; Jangir, P.; Kaur, S.; Kapoor, R. Mushroom-derived nutraceuticals in the 21st century: An appraisal and future perspectives. J. Future Foods 2025, 5, 342–360. [Google Scholar] [CrossRef]
  6. Zade, S.; Upadhyay, T.K.; Rab, S.O.; Sharangi, A.B.; Lakhanpal, S.; Alabdallah, N.M.; Saeed, M. Mushroom-derived bioactive compounds pharmacological properties and cancer targeting: A holistic assessment. Discov. Oncol. 2025, 16, 654. [Google Scholar] [CrossRef] [PubMed]
  7. Li, M.; Yu, L.; Zhao, J.; Zhang, H.; Chen, W.; Zhai, Q.; Tian, F. Role of dietary edible mushrooms in the modulation of gut microbiota. J. Funct. Foods 2021, 83, 104538. [Google Scholar] [CrossRef]
  8. Zhao, S.; Gao, Q.; Rong, C.; Wang, S.; Zhao, Z.; Liu, Y.; Xu, J. Immunomodulatory effects of edible and medicinal mushrooms and their bioactive immunoregulatory products. J. Fungi 2020, 6, 269. [Google Scholar] [CrossRef] [PubMed]
  9. Abbaspour, N. Fermentation’s pivotal role in shaping the future of plant-based foods: An integrative review of fermentation processes and their impact on sensory and health benefits. Appl. Food Res. 2024, 26, 100011. [Google Scholar] [CrossRef]
  10. Coelho, L.C.; Favilla, L.D.; de Castro, T.B.; Leal, M.C.B.D.M.; Hoffmann, C.; Bocca, A.L. Auricularia auricula’s Exopolysaccharide Mitigates DSS-Induced Colitis Through Dectin–1-Mediated Immunomodulation and Microbiota Remodeling. Pharmaceuticals 2025, 18, 1085. [Google Scholar] [CrossRef] [PubMed]
  11. Dourado, J.d.A.E.; Lopes, S.Q.; Jimenez, D.E.Q.; Ramos, R.S.; Ferreira, I.M. Identification of novel progesterone receptor (PR) inhibitors (Homo sapiens) from metabolites of biotransformation fungal: A bioinformatics approach. Pharmaceuticals 2025, 18, 136. [Google Scholar] [CrossRef] [PubMed]
  12. Fu, Y.; Jiang, T.; Fang, X.; Chen, Y.; Li, J.; Huang, S.; Li, F.; Jin, D. Integrating network pharmacology and experimental validation to explore the effect and mechanism of Inonotus obliquus polysaccharide in the treatment of rheumatoid arthritis. Pharmaceuticals 2025, 18, 1017. [Google Scholar] [CrossRef] [PubMed]
  13. Kała, K.; Cicha-Jeleń, M.; Hnatyk, K.; Krakowska, A.; Sułkowska-Ziaja, K.; Szewczyk, A.; Lazur, J.; Muszyńska, B. Coffee with Cordyceps militaris and Hericium erinaceus fruiting bodies as a source of essential bioactive substances. Pharmaceuticals 2024, 17, 955. [Google Scholar] [CrossRef] [PubMed]
  14. Santos, A.K.M.; dos Santos, B.A.; Farias, J.R.; de Morais, S.V.; Vasconcelos, C.C.; Guerra, R.N.M.; Rodrigues-Filho, E.; Lopes, A.J.O.; Cantanhede Filho, A.J. Effect of Mn(II) and Co(II) on anti-Candida metabolite production by Aspergillus sp. an endophyte isolated from Dizygostemon riparius (Plantaginaceae). Pharmaceuticals 2024, 17, 1678. [Google Scholar] [CrossRef] [PubMed]
  15. Wang, N.; Chen, C.; Li, Q.; Liang, Q.; Liu, Y.; Shao, Z.; Liu, X.; Zhou, Q. Isolation of ten new sesquiterpenes and new abietane-type diterpenoid with immunosuppressive activity from marine fungus Eutypella sp. Pharmaceuticals 2025, 18, 737. [Google Scholar] [CrossRef] [PubMed]
  16. Song, Y.; Feng, Y.; Liu, G.; Duan, Y.; Zhang, H. Research progress on edible mushroom polysaccharides as a novel therapeutic strategy for inflammatory bowel disease. Int. J. Biol. Macromol. 2025, 305, 140994. [Google Scholar] [CrossRef] [PubMed]
  17. Venkatachalam, P.; Muthu, M.; Gopal, J. Reviewing the audacity of elixirs of inflammatory bowel disease from mushroom β-glucans: The solved and unresolved. Carbohydr. Polym. 2025, 348, 122832. [Google Scholar] [CrossRef] [PubMed]
  18. Shah, Z.A.; Khan, K.; Shah, T.; Ahmad, N.; Khan, A. Isolation, characterization and pharmacological investigations of secondary metabolites from Aspergillus ficuum via experimental and computational techniques. RSC Adv. 2024, 14, 36527–36537. [Google Scholar] [CrossRef] [PubMed]
  19. Kirdeeva, Y.; Fedorova, O.; Daks, A.; Barlev, N.; Shuvalov, O. How should the worldwide knowledge of traditional cancer healing be integrated with herbs and mushrooms into modern molecular pharmacology? Pharmaceuticals 2022, 15, 868. [Google Scholar] [CrossRef] [PubMed]
  20. Rathore, H.; Prasad, S.; Sharma, S. Mushroom nutraceuticals for improved nutrition and better human health: A review. PharmaNutrition 2017, 5, 35–46. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kała, K. Advances in Fungal Natural Products: Insights into Bioactivity and Therapeutic Potential. Pharmaceuticals 2025, 18, 1313. https://doi.org/10.3390/ph18091313

AMA Style

Kała K. Advances in Fungal Natural Products: Insights into Bioactivity and Therapeutic Potential. Pharmaceuticals. 2025; 18(9):1313. https://doi.org/10.3390/ph18091313

Chicago/Turabian Style

Kała, Katarzyna. 2025. "Advances in Fungal Natural Products: Insights into Bioactivity and Therapeutic Potential" Pharmaceuticals 18, no. 9: 1313. https://doi.org/10.3390/ph18091313

APA Style

Kała, K. (2025). Advances in Fungal Natural Products: Insights into Bioactivity and Therapeutic Potential. Pharmaceuticals, 18(9), 1313. https://doi.org/10.3390/ph18091313

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop